Progress in Cardiovascular Diseases
Volume 45, Issue 2 , Pages 139-156 , September 2002

The role of low-molecular–weight heparin in cardiovascular diseases

References 

  1. Weitz JI. Low-molecular–weight heparins. N Engl J Med. 1997;337:688–698
  2. Choay J, Lormeau JC, Petitou M, et al.  Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci. 1981;370:644–649
  3. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation. 1994;89:1449–1468
  4. Theroux P, Waters D, Lam J, Juneau M, et al.  J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141–145
  5. Cosmi B, Fredenburgh JC, Rischke J, et al.  Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular–weight heparin, and dermatan sulfate. Circulation. 1997;95:118–124
  6. Young E, Cosmi B, Weitz J, et al.  Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost. 1993;70:625–630
  7. Mombelli G, Marchetti O, Haeberli A, et al.  Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. Am Heart J. 1998;136:1106–1113
  8. Stricker H, Marchetti O, Haeberli A, et al.  Hemostatic activation under anticoagulant treatment: A comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thromb Haemost. 1999;82:1227–1231
  9. Barrowcliffe T, Johnson E, Thomas D. Low Molecular Weight Heparin. Chicester, UK: John Wiley & Sons; 1992;
  10. Bounameaux H. Low Molecular Weight Heparins in Prophylaxix and Therapy of thromboembolic Disease. New York, NY: Marcel Dekker; 1994;
  11. Lane DA, Denton J, Flynn AM, et al.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984;218:725–732
  12. Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis. 1991;21:254–257
  13. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular–weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256
  14. Montalescot G, Philippe F, Ankri A, et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998;98:294–299
  15. Antman EM, Handin R. Low-molecular–weight heparins: An intriguing new twist with profound implications. Circulation. 1998;98:287–289
  16. Kuijer P, Prins M, Buller H. Low-molecular–weight heparins: Treatment of venous thromboembolism. In:  Sasahara A,  Loscalzo J editor. Advances in Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker; 1997;p. 129–147
  17. Simonneau G, Sors H, Charbonnier B, et al.  A comparison of low-molecular–weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997;337:663–669
  18. Levine M, Gent M, Hirsh J, et al.  A comparison of low-molecular–weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677–681
  19. Koopman MM, Prandoni P, Piovella F, et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular–weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682–687
  20. Low-molecular–weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997;337:657–662
  21. Decousus H, Leizorovicz A, Parent F, et al.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409–415
  22. Gould MK, Dembitzer AD, Doyle RL, et al.  Low-molecular–weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800–809
  23. Ellison J, Thomson AJ, Conkie JA, et al.  Thromboprophylaxis following caesarean section—A comparison of the antithrombotic properties of three low- molecular–weight heparins—dalteparin, enoxaparin and tinzaparin. Thromb Haemost. 2001;86:1374–1378
  24. van der Heijden JF, Prins MH, Buller HR. Low-molecular–weight heparins: Are they interchangeable?. Haemostasis. 2000;30(suppl 2):148–157 discussion 146-147
  25. Eriksson BI, Bauer KA, Lassen MR, et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298–1304
  26. Bauer KA, Eriksson BI, Lassen MR, et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305–1310
  27. Heit JA, Colwell CW, Francis CW, et al.  Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study. Arch Intern Med. 2001;161:2215–2221
  28. Theroux P, Ouimet H, McCans J, et al.  Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111
  29. Group TR. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. 1990;336:827–830
  30. Holdright D, Patel D, Cunningham D, et al.  Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39–45
  31. Oler A, Whooley MA, Oler J, et al.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–815
  32. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation. 1994;90:1631–1637
  33. Patrono C, Coller B, Dalen JE, et al.  Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest. 1998;114:470S–488S
  34. Low-molecular–weight heparin during instability in coronary arterydisease. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996;347:561–568
  35. Long-term low-molecular–mass heparin in unstable coronary-artery disease . FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet. 1999;354:701–707
  36. Gurfinkel EP, Manos EJ, Mejail RI, et al.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313–318
  37. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction . FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999;20:1553–1562
  38. Klein W, Buchwald A, Hillis SE, et al.  Comparison of low-molecular–weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997;96:61–68
  39. Cohen M, Demers C, Gurfinkel EP, et al.  A comparison of low-molecular–weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–452
  40. Goodman SG, Cohen M, Bigonzi F, et al.  Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693–698
  41. Antman EM, McCabe CH, Gurfinkel EP, et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  42. Antman EM, Cohen M, Radley D, et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
  43. Eikelboom JW, Anand SS, Malmberg K, et al.  Unfractionated heparin and low-molecular–weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet. 2000;355:1936–1942
  44. Cohen M, Turpie AG. Management of unstable angina and myocardial infarction. Lancet. 2000;356:1193–1194
  45. Simoons M. PENTUA (Pentasaccharide in unstable angina), in American Heart Association Scientific Sessions. 2001; Anaheim, CA
  46. Kong DF, Califf RM, Miller DP, et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835
  47. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284:1549–1558
  48. PRISM-PLUS investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488–1497
  49. Kleiman NS, Lincoff AM, Flaker GC, et al.  Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000;101:751–757
  50. Cohen M, Theroux P, Weber S, et al.  Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol. 1999;71:273–281
  51. Ferguson J. NICE-3 (National Investigators Collaborating on Enoxaparin-3): Prospective, open label, non-randomised observational safety study on the combination of LMW heparin with the clinically available IIb/IIIa antagonists in 600 patients with acute coronary syndromes, in. 22nd Congress of the European Society of Cardiology. 2000; Amsterdam, Netherlands
  52. Wallentin L. GUSTO IV Substudy of LMWH, in 22nd Congress of the European Society of Cardiology. Amsterdam, Netherlands: Eur Heart J; 2000;
  53. Cohen M. ACUTE II: First randomized data on IIb/IIIa blockers and LMW heparin in ACS, in American Heart Association Scientific Sessions. 2000; New Orleans, LA
  54. Mukherjee D, Mahaffey K, Moliterno D, et al.  The promise of combined low-molecular–weight heparin and platelet glycoprotein IIb/IIIa inhibition—Results from PARAGON B. Circulation. 2000;102:11–591
  55. Blazing MA, De Lemos JA, Dyke CK, et al.  The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular–weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001;142:211–217
  56. Cohen M, Maritz F, Gensini GF, et al.  The TETAMI trial: The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: Methods and design. J Thromb Thrombolysis. 2000;10:241–246
  57. Hanke H, Oberhoff M, Hanke S, et al.  Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular–weight heparin. Circulation. 1992;85:1548–1556
  58. Buchwald AB, Unterberg C, Nebendahl K, et al.  low-molecular–weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation. 1992;86:531–537
  59. Faxon DP, Spiro TE, Minor S, et al.  Low-molecular– weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation. 1994;90:908–914
  60. Cairns JA, Gill J, Morton B, et al.  Fish oils and low-molecular–weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation. 1996;94:1553–1560
  61. Karsch KR, Preisack MB, Baildon R, et al.  Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol. 1996;28:1437–1443
  62. Kiesz RS, Buszman P, Martin JL, et al.  Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). Circulation. 2001;103:26–31
  63. Rabah MM, Premmereur J, Graham M, et al.  Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:1391–1395
  64. Kereiakes DJ, Grines C, Fry E, et al.  Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–278
  65. Collet JP, Montalescot G, Lison L, et al.  Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658–663
  66. Kereiakes DJ, Fry E, Matthai W, et al.  Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: “NICE guys finish first”. J Invasive Cardiol. 2000;12(suppl A):1A–5A
  67. Kereiakes DJ, Kleiman NS, Fry E, et al.  Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J. 2001;141:348–352
  68. Kontny F, Dale J, Abildgaard U, et al.  Randomized trial of low-molecular–weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962–969
  69. Glick A, Kornowski R, Michowich Y, et al.  Reduction of reinfarction and angina with use of low-molecular–weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol. 1996;77:1145–1148
  70. Alsonso A. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2001;37:64A
  71. Wallentin L, Dellborg DM, Lindahl B, et al.  The low-molecular–weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clin Cardiol. 2001;24:I12–I14
  72. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin . The ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  73. Ross AM, Molhoek P, Lundergan C, et al.  Randomized comparison of enoxaparin, a low-molecular–weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001;104:648–652
  74. Antman E. ENoxaparin and TNK-TPA with or without GP IIb/IIIa Inhibitor as REperfusion strategy in ST Elevation MI (ENTIRE-TIMI 23) trial, in: XXIII Congress of the European Society of Cardiology. Stockholm, Sweden: Eur Heart J; 2001;
  75. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?. J Am Coll Cardiol. 2000;35:1699–1712
  76. Nightingale SL. From the Food and Drug Administration. JAMA. 1993;270:1672
  77. Hirsh J, Warkentin TE, Raschke R, et al.  Heparin and low-molecular–weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114:489S–510S
  78. Ryan TJ, Antman EM, Brooks NH, et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911
  79. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673–682
  80. Hirsh J, Anand SS, Halperin JL, et al.  Guide to anticoagulant therapy. Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018
  81. Turpie AG, Antman EM. Low-molecular–weight heparins in the treatment of acute coronary syndromes. Arch Intern Med. 2001;161:1484–1490
  82. Simoons M. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction—The Acute Myocardial Infarction-Streptokinase (AMI-SK) trial. In: ACC 50th Annual Scientific Session—Late-Breaking Clinical Trials III, Orlando, FL. 2001;

☆ Address reprint requests to Eric J. Topol, MD, FACC, Provost and Chief Academic Officer, Chairman, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F 25, 9500 Euclid Ave, Cleveland, OH 44195.

PII: S0033-0620(02)70004-2

doi: 10.1053/pcad.2002.127679

Progress in Cardiovascular Diseases
Volume 45, Issue 2 , Pages 139-156 , September 2002

Article Tools

* Image Usage & Resolution